Treatment of congestive heart failure

Abstract

A method of treating congestive heart failure (CHF) in a human patient comprises treating an aliquot of the patient's blood ex vivo with at least one stressor selected from the group consisting of a temperature above or below body temperature, an electromagnetic emission and an oxidative environment, followed by administering the aliquot of treated blood to the patient. The treatment can be used on its own or as an adjunctive therapy in combination with conventional CHF treatments.

1 - 26 . (canceled)  
   
   
       27 . A method of treating congestive heart failure (CHF) in a human patient suffering therefrom, comprising: 
 (a) treating an aliquot of the patient's blood ex vivo with a stressor comprising an oxidizing agent; and    (b) administering the aliquot of blood step (a) to the patient, wherein the aliquot has a volume sufficient to treat CHF in the patient.    
   
   
       28 . The method of  claim 27 , wherein said stressor further comprises electromagnetic emissions and/or a temperature above or below body temperature.  
   
   
       29 . The method of  claim 28 , wherein all of the stressors are simultaneously administered to the aliquot.  
   
   
       30 . The method of  claim 28 , wherein any two of the stressors are simultaneously administered to the aliquot.  
   
   
       31 . The method of  claim 28 , wherein the electromagnetic emission comprises ultraviolet light having one or more UV-C band wavelengths.  
   
   
       32 . The method of  claim 28 , wherein the temperature to which the aliquot is cooled or heated is a temperature which does not result in substantial hemolysis of the blood in the aliquot.  
   
   
       33 . The method of  claim 32 , wherein the mean temperature of the blood in the aliquot is iii the range of from about 0° C. to about 36.5° C.  
   
   
       34 . The method of  claim 32 , wherein the mean temperature of the blood in the aliquot is in the range of from about 10° C. to about 30° C.  
   
   
       35 . The method of  claim 32 , wherein the temperature is in the range of from about 40° C. to about 50° C.  
   
   
       36 . The method of  claim 35 , wherein the temperature is 42.5±1° C.  
   
   
       37 . The method of  claim 27 , wherein the oxidizing agent is introduced into the blood aliquot in an amount which does not give rise to excessive levels of cell damage.  
   
   
       38 . The method of  claim 27 , wherein the volume of the aliquot is up to about 400 ml.  
   
   
       39 . The method of  claim 38 , wherein the volume of the aliquot is about 10 ml.  
   
   
       40 . The method of  claim 38 , wherein the volume of the aliquot is about 2 ml.  
   
   
       41 . The method of  claim 27 , wherein the aliquot is subjected to the stressor for a period of up to about 60 minutes.  
   
   
       42 . The method of  claim 41 , wherein the aliquot is subjected to the stressor for a period of about 3 minutes.  
   
   
       43 . The method of  claim 27 , wherein the blood is administered to the mammal by a method suitable for vaccination selected from the group consisting of intra-arterial injection, intramuscular injection, intravenous injection, subcutaneous injection, intraperitoneal injection, and oral, nasal or rectal administration.  
   
   
       44 . A combination treatment for congestive heart allure (CHF) in a human patient suffering therefrom, the combination treatment including the administration to the patient of an aliquot of the patient's own blood which has been treated selected from the group ex vivo with a stressor comprising an oxidizing agent and selected from the group consisting of nitrates, β-blockers, ACE inhibitors, AT receptor blocking agents, aldosterone antagonists, calcium channel blocking agents, TNF blocking agents, suppressors of production of TNF-α, sodium and fluid restriction, diuretics and digitalis wherein the aliquot has a volume sufficient to treat CHF in the patient.  
   
   
       45 . The combination treatment of  claim 44 , wherein the suppressors of production of TNF-α are selected from the group consisting of pentoxifyline, TACE inhibitors, amrinone, adenosine, thalidomide and dexamethasone.  
   
   
       46 . A method of treating congestive heart failure (CHF) in a human patient suffering therefrom, comprising: 
 a) treating an aliquot of the patient's blood ex vivo simultaneously, for a time up to 60 minutes, with a combination of stressors comprising (1) a mixture of ozone gas and medical grade oxygen, the ozone gas being contained in the mixture in a concentration of up to about 300 μg/ml; (2) ultraviolet light having one or more UV/C band wavelengths; and (3) temperature in the range of from about 37° C. to about 55° C.;    b) administering the aliquot of the treated in step a) to the patient, wherein the aliquot has a volume sufficient to treat the CHF in the patient.